Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
6.65
+0.13 (1.99%)
At close: Jun 12, 2026, 4:00 PM EDT
6.78
+0.13 (1.95%)
After-hours: Jun 12, 2026, 5:15 PM EDT

Relmada Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-58.88-57.39-79.98-98.79-157.04-125.75
Depreciation & Amortization
-----0
Stock-Based Compensation
14.1115.8730.1943.8144.1940.49
Other Adjustments
0.45-0.32-0.380.24-1.551.25
Change in Receivables
---0.51-0.51-
Changes in Accounts Payable
2.07-2.560.62-1.760.422.85
Changes in Accrued Expenses
-0.66-1.3-2.531.483.34-0.39
Changes in Other Operating Activities
-0.78-0.090.322.847.35-10.32
Operating Cash Flow
-42.79-45.79-51.76-51.66-103.8-91.87
Purchases of Investments
-232.86-83.83-12.08-90.46-47.29-222.98
Proceeds from Sale of Investments
34.1335.6963.64140.9267.03168.86
Investing Cash Flow
-198.73-48.1451.5650.4519.73-54.12
Issuance of Common Stock
16093.640.25-45.07187.94
Net Common Stock Issued (Repurchased)
16093.640.25-45.07187.94
Other Financing Activities
-3.5-0.07-0.29-0.1-0.05-
Financing Cash Flow
250.1493.56-0.04-0.145.02187.94
Net Cash Flow
8.63-0.36-0.23-1.3-39.0541.95
Free Cash Flow
-42.79-45.79-51.76-51.66-103.8-91.87
Free Cash Flow Per Share
-0.80-1.16-1.72-1.72-3.50-5.23
Levered Free Cash Flow
-58.26-61.33-81.56-96.22-145.94-133.62
Unlevered Free Cash Flow
-59.72-63.05-85.47-101.13-150.14-133.57
SEC Filings: 10-K · 10-Q